Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway

The therapeutic effects of standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy for prevalent lymphoma diffuse large B-cell lymphoma (DLBC, DLBCL) still require improvement. Cancer-related aurora-kinase-A (AURKA) may work as a target for DLBCL treatment and its effect on...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shaoxiong, Sun, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806979/
https://www.ncbi.nlm.nih.gov/pubmed/34565287
http://dx.doi.org/10.1080/21655979.2021.1985346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806979/
https://www.ncbi.nlm.nih.gov/pubmed/34565287
http://dx.doi.org/10.1080/21655979.2021.1985346

Ejemplares similares